Pixclara® (18F-⁠FET) Is Generally Well Tolerated1

Actor portrayals

No serious adverse events were reported in either study that evaluated the safety of Pixclara®

Shield displaying 382 patients

Clinical trials experience

The safety of Pixclara® is based on the analyses of 382 patients from 2 clinical trials who received at least 1 dose of Pixclara®.a

Adverse reactions that occurred in <0.5% of patients were:

Nausea

Injection site reaction

Fatigue and malaise

  • Headache occurred in 0.5% of patients

Pediatric patients

The safety profile observed in pediatric patients (1 month of age and older) was consistent with the safety profile in adult patients.

Learn how Pixclara® is dosed and administered.

View Information

aBecause clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.